HDL biology
A 12-week lycopene trial lowers serum CETP activity and boosts LCAT and paraoxonase-1 activity in overweight middle-aged adults (J Nutr Biochem 2013)
Original title: Lycopene intervention reduces inflammation and improves HDL functionality in moderately overweight middle-aged individuals
In a 12-week randomized trial, 54 moderately overweight, middle-aged individuals received a control diet (under 10 mg lycopene/week), a lycopene-rich diet (224-350 mg lycopene/week), or a lycopene supplement (70 mg lycopene/week). Serum and HDL2/HDL3 lycopene concentrations increased with both lycopene interventions (P<.001 for all), while serum amyloid A decreased in serum after the supplement and in HDL3 after both interventions (P<.05 for all). Paraoxonase-1 activity increased in serum and HDL2/HDL3 with both lycopene groups (P<.05 for all). The activity of cholesteryl ester transfer protein (CETP) decreased in serum following the lycopene supplement, while lecithin-cholesterol acyltransferase activity increased in serum and HDL3 following both interventions (P<.05 for all).
Original abstract
The management of overweight subjects by interventions aimed at reducing inflammation is highly desirable. To date, observational studies have identified a link between increased dietary antioxidant intake and reduced cardiovascular morbidity. However, direct trial evidence regarding the ability of antioxidants to influence inflammation is lacking. Therefore, this study examined lycopene's ability to lower systemic and high-density lipoprotein (HDL)-associated inflammation in moderately overweight middle-aged subjects. Serum was collected before and after a 12-week intervention from 54 moderately overweight, middle-aged individuals. Subjects were randomised to one of three groups: control diet (<10 mg lycopene/week), lycopene-rich diet (224-350 mg lycopene/week) and lycopene supplement (70 mg lycopene/week). HDL was subfractionated into HDL(2&3) by rapid ultracentrifugation. Compliance was monitored by assessing lycopene concentration in serum and HDL(2&3). Systemic and HDL-associated inflammation was assessed by measuring serum amyloid A (SAA) levels. HDL functionality was determined by monitoring the activities of paraoxonase-1 (PON-1), cholesteryl ester transfer protein (CETP) and lecithin cholesterol acyltransferase (LCAT). Lycopene increased in serum and HDL(2&3) following both lycopene interventions (P<.001, for all), while SAA decreased in serum following the lycopene supplement and in HDL(3) following both lycopene interventions (P<.05 for all). PON-1 activity increased in serum and HDL(2&3) in both lycopene groups (P<.05, for all). Furthermore, the activity of CETP decreased in serum following the lycopene supplement, while the activity of LCAT increased in serum and HDL(3) following both lycopene interventions (P<.05 for all). These results demonstrate that in moderately overweight, middle-aged subjects, increasing lycopene intake leads to changes to HDL(2&3), which we suggest enhanced their antiatherogenic properties. Overall, these results show the heart-protective properties of increased lycopene intake.
Summary written by cetpinhibition.org from the published abstract; figures as published. Page updated 19 August 2026. Methods.